Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform

Feb 23 2018

• By Mandy Jackson

3d illustration of T cells or cancer cells

Related Content

Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval

Sep 04 2017

Cellectis soars as Pfizer fronts $80m for immuno-oncology

Jun 19 2014

Gilead Acquisition Of Cell Design: The Next Logical Step

Dec 08 2017

Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo

Jan 04 2018

Novartis to use gene editing tool with CAR-T therapies

Jan 07 2015

Janssen touts Transposagen technology in CAR-T collaboration

Nov 25 2014

BioNotebook: Sangamo/Biogen, Adamas/Forest, Zymeworks/Lilly, Sunesis

Jan 10 2014

Sangamo Looks Forward After Shire Returns Hemophilia Rights

Sep 03 2015

Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy

Aug 29 2017

Juno Looks To Move CAR-T To Solid Tumors Via Editas Deal

May 27 2015

Related Companies

Gilead Sciences, Inc.

Sangamo Therapeutics, Inc.

Kite Pharma, Inc.

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

Sanofi

CRISPR Therapeutics AG

Johnson & Johnson

Poseida Therapeutics, Inc.

Cellectis SA

Bristol Myers Squibb Company

Editas Medicine

Novartis AG

Intellia Therapeutics, Inc.

Additional Topics

Deals Business Strategies ImmunoOncology Commercial Cancer BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window